Evaluating alternative compounds for strongyloidiasis therapy: Novel insights from larval migration inhibition test

María Cambra-Pellejà,Elora Valderas-García,Rafael Balaña-Fouce,Jennifer de la Vega,Esther del Olmo,Jennifer Antwi-Ekwuruke,Lara Linnemann,Lennart Heepmann,Minka Breloer,María Martínez-Valladares
DOI: https://doi.org/10.1371/journal.pntd.0012532
2024-10-08
PLoS Neglected Tropical Diseases
Abstract:Strongyloidiasis is a neglected tropical disease estimated to affect more than 600 million people worldwide. Recently, the World Health Organization road map on neglected tropical diseases 2021–2030 has put the focus on strongyloidiasis, including this disease within its mass drug administration campaigns. With the use of ivermectin in extensive treatment of all populations at-risk, identifying effective therapeutic alternatives is crucial in case ivermectin resistance arises. The objective of the present study was the development of a larval migration inhibition assay to evaluate the anthelmintic efficacy of commercial drugs and diamine and aminoalcohol derivatives against infective Strongyloides ratti third stage larvae. Through this technique, we successfully screened and estimated the in vitro anthelmintic efficacy of six commercial drugs, seven diamine derivatives and eight aminoalcohol derivatives. Unexpectedly, the half-maximal effective concentration of ivermectin and moxidectin (2.21 and 2.34 μM, respectively) were observed as the highest value obtained among all commercial drugs tested by this in vitro technique. Moreover, some diamine and aminoalcohol derivatives showed superior efficacy inhibiting S . ratti motility compared to ivermectin, with five compounds (AA23, AA34, AO2 AO7 and AO14b) also displaying selectivity indexes on HepG2 and Caco2 higher than 1. These findings underscore the potential of these derivatives as promising alternatives for strongyloidiasis treatment, warranting further investigation and in vivo efficacy assessment. Strongyloidiasis, a parasitic infection affecting over 600 million people worldwide, is increasingly recognized in global health initiatives. Caused by the nematode Strongyloides stercoralis , it predominantly occurs in tropical and subtropical regions. Transmission results through contact with soil contaminated by infectious larvae, leading to a spectrum of clinical symptoms from mild gastrointestinal discomfort to potentially life-threatening complications, especially in individuals with weakened immune systems. Despite its designation as a neglected tropical disease, concerns regarding the development of drug resistance highlight the need to explore alternative treatment strategies. In our study, we employed innovative methods to evaluate the in vitro efficacy of various drug candidates against Strongyloides ratti larvae, representing a crucial step in identifying novel therapies for human strongyloidiasis. Our findings revealed that some of the novel compounds tested, showed superior efficacy in inhibiting parasite motility, suggesting potential benefits for patient treatment outcomes. Our study underscores the urgent need for diversified treatment approaches in combating strongyloidiasis.
tropical medicine,parasitology
What problem does this paper attempt to address?